index,token,order,concept_token,token_classifier,idphrase,concept,id_trial,cuid,umlstokens,concept_phrase_type,lang_token,weightuser
,Bruton Tyrosine Kinase,0,GGP,craft,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",warnings,NCT05006716,C0218158,Agammaglobulinaemia tyrosine kinase,FDA,en,0
,Protein Degrader,0,CHEBI,craft,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",warnings,NCT05006716,C0597297,"Protein Degradation, Metabolic",FDA,en,0
,Bruton Tyrosine Kinase Targeted Protein,0,PROTEIN,jnlpba,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",warnings,NCT05006716,C0218158,Agammaglobulinaemia tyrosine kinase,FDA,en,0
,Tyrosine,0,CHEMICAL,jnlpba,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",warnings,NCT05006716,C0041485,tyrosine,FDA,en,0
,B-Cell Malignancies,0,DISEASE,jnlpba,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",warnings,NCT05006716,C0023434,Chronic Lymphocytic Leukemia,FDA,en,0
,Bruton Tyrosine Kinase,0,GENE_OR_GENE_PRODUCT,bionlp,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",warnings,NCT05006716,C0218158,Agammaglobulinaemia tyrosine kinase,FDA,en,0
,Patients,0,ORGANISM,bionlp,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",warnings,NCT05006716,C0030705,Patients,FDA,en,0
,B-Cell Malignancies,0,CANCER,bionlp,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",warnings,NCT05006716,C0023434,Chronic Lymphocytic Leukemia,FDA,en,0
,TIME,0,GENE_OR_GENE_PRODUCT,bionlp,Take TIME for Your Child's Health: A Health Promotion Campaign Targeting Caregivers of Young Children,pediatric_use,NCT01290848,C0040223,Time,FDA,en,0
,Children,0,ORGANISM,bionlp,Take TIME for Your Child's Health: A Health Promotion Campaign Targeting Caregivers of Young Children,pediatric_use,NCT01290848,C0008059,Child,FDA,en,0
,Clemizole Hydrochloride,0,GGP,craft,"A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)",adverse_reactions,NCT04462770,C0772142,Clemizole Hydrochloride,FDA,en,0
,EPX-100,0,PROTEIN,jnlpba,"A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)",adverse_reactions,NCT04462770,,,FDA,en,0
,Clemizole Hydrochloride,0,CHEMICAL,jnlpba,"A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)",adverse_reactions,NCT04462770,C0772142,Clemizole Hydrochloride,FDA,en,0
,Dravet Syndrome,0,DISEASE,jnlpba,"A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)",adverse_reactions,NCT04462770,C0751122,Infantile Severe Myoclonic Epilepsy,FDA,en,0
,Hydrochloride,0,SIMPLE_CHEMICAL,bionlp,"A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)",adverse_reactions,NCT04462770,C1512523,hydrochloride,FDA,en,0
,Children,0,ORGANISM,bionlp,"A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)",adverse_reactions,NCT04462770,C0008059,Child,FDA,en,0
,Lenvatinib,0,CHEBI,craft,"Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)",indications,NCT04662710,C2986924,lenvatinib,FDA,en,0
,Lenvatinib,0,CHEMICAL,jnlpba,"Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)",indications,NCT04662710,C2986924,lenvatinib,FDA,en,0
,MK-3475,0,CHEMICAL,jnlpba,"Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)",indications,NCT04662710,C3660977,MK-3475,FDA,en,0
,Advanced/Metastatic Gastroesophageal Adenocarcinoma,0,DISEASE,jnlpba,"Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)",indications,NCT04662710,C5204519,Advanced Gastroesophageal Junction Adenocarcinoma,FDA,en,0
,Lenvatinib,0,SIMPLE_CHEMICAL,bionlp,"Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)",indications,NCT04662710,C2986924,lenvatinib,FDA,en,0
,MK-3475,0,SIMPLE_CHEMICAL,bionlp,"Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)",indications,NCT04662710,C3660977,MK-3475,FDA,en,0
,MK-1026,0,GGP,craft,A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies,pediatric_use,NCT04728893,C5557456,MK-1026,FDA,en,0
,Adenocarcinoma,0,CANCER,bionlp,"Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)",indications,NCT04662710,C0001418,Adenocarcinoma,FDA,en,0
,CZP,0,CHEBI,craft,"Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)",pediatric_use,NCT04123795,C1861828,"Cataract, Zonular Pulverulent 1",FDA,en,0
,Single Open-Label Arm,0,PROTEIN,jnlpba,"Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)",pediatric_use,NCT04123795,,,FDA,en,0
,Certolizumab,0,CHEMICAL,jnlpba,"Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)",pediatric_use,NCT04123795,C1872109,certolizumab pegol,FDA,en,0
,CZP,0,CHEMICAL,jnlpba,"Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)",pediatric_use,NCT04123795,C1861828,"Cataract, Zonular Pulverulent 1",FDA,en,0
,Psoriasis,0,DISEASE,jnlpba,"Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)",pediatric_use,NCT04123795,C0033860,Psoriasis,FDA,en,0
,Certolizumab,0,SIMPLE_CHEMICAL,bionlp,"Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)",pediatric_use,NCT04123795,C1872109,certolizumab pegol,FDA,en,0
,CZP,0,SIMPLE_CHEMICAL,bionlp,"Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)",pediatric_use,NCT04123795,C1861828,"Cataract, Zonular Pulverulent 1",FDA,en,0
,ALS,0,DISEASE,jnlpba,Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS (CAPTURE ALS Smarwatch),warnings,NCT05830214,C0002736,Amyotrophic Lateral Sclerosis,FDA,en,0
,Smartwatch,0,GENE_OR_GENE_PRODUCT,bionlp,Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS (CAPTURE ALS Smarwatch),warnings,NCT05830214,C5561872,Smartwatches,FDA,en,0
,HBsAg Monoclonal Ab,0,PROTEIN,jnlpba,Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection,warnings,NCT06216470,C0019168,Hepatitis B Surface Antigens,FDA,en,0
,HBsAg,0,CHEMICAL,jnlpba,Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection,warnings,NCT06216470,C0019168,Hepatitis B Surface Antigens,FDA,en,0
,Hepatitis B,0,DISEASE,jnlpba,Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection,warnings,NCT06216470,C0019163,Hepatitis B,FDA,en,0
,HBsAg Monoclonal Ab VIR-3434,0,ORGANISM,bionlp,Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection,warnings,NCT06216470,C0019168,Hepatitis B Surface Antigens,FDA,en,0
,Hepatitis B,0,ORGANISM,bionlp,Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection,warnings,NCT06216470,C0019163,Hepatitis B,FDA,en,0
,Lateral Sclerosis,0,DISEASE,jnlpba,Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis,adverse_reactions,NCT02405182,C0154682,Lateral Sclerosis,FDA,en,0
,Lateral,0,TISSUE,bionlp,Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis,adverse_reactions,NCT02405182,C0205093,Lateral,FDA,en,0
,FLT3 Mutations,0,GGP,craft,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C0251006,"FLT3 protein, human",FDA,en,0
,FLT3,0,PROTEIN,jnlpba,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C0251006,"FLT3 protein, human",FDA,en,0
,AML,0,CHEMICAL,jnlpba,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C0023467,"Leukemia, Myelocytic, Acute",FDA,en,0
,Gemtuzumab Ozogamicin,0,CHEMICAL,jnlpba,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C1533699,gemtuzumab ozogamicin,FDA,en,0
,CPX-351,0,CHEMICAL,jnlpba,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C2346682,CPX-351,FDA,en,0
,UCN-01,0,CHEMICAL,jnlpba,A Phase I Study of UCN-01 in Combination With Topotecan in Patients With Solid Tumors,pediatric_use,NCT00045175,C0950721,UCN 01,FDA,en,0
,Patients,0,ORGANISM,bionlp,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C0030705,Patients,FDA,en,0
,AML,0,CANCER,bionlp,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C0023467,"Leukemia, Myelocytic, Acute",FDA,en,0
,Gemtuzumab Ozogamicin,0,SIMPLE_CHEMICAL,bionlp,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C1533699,gemtuzumab ozogamicin,FDA,en,0
,CPX-351,0,SIMPLE_CHEMICAL,bionlp,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C2346682,CPX-351,FDA,en,0
,FLT3,0,GENE_OR_GENE_PRODUCT,bionlp,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",warnings,NCT04293562,C0251006,"FLT3 protein, human",FDA,en,0
,68Ga-DOTATOC PET/CT,0,PROTEIN,jnlpba,Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients,warnings,NCT03583528,C1742831,dotatate gallium ga-68,FDA,en,0
,NET,0,CHEMICAL,jnlpba,Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients,warnings,NCT03583528,C0812375,ELK3 gene,FDA,en,0
,NET Patients,0,CANCER,bionlp,Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients,warnings,NCT03583528,C0812375,ELK3 gene,FDA,en,0
,Cyproheptadine Hydrochloride,0,CL,craft,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0010620,cyproheptadine,FDA,en,0
,Periactin,0,GGP,craft,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0031017,periactin,FDA,en,0
,Acetate,0,CHEBI,craft,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0000975,acetate,FDA,en,0
,Cyproheptadine Hydrochloride,0,CHEMICAL,jnlpba,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0010620,cyproheptadine,FDA,en,0
,Periactin,0,CHEMICAL,jnlpba,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0031017,periactin,FDA,en,0
,Megestrol Acetate,0,CHEMICAL,jnlpba,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0065879,megestrol acetate,FDA,en,0
,Megace,0,CHEMICAL,jnlpba,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0700004,Megace,FDA,en,0
,Cachexia,0,DISEASE,jnlpba,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0006625,Cachexia,FDA,en,0
,Cyproheptadine Hydrochloride,0,SIMPLE_CHEMICAL,bionlp,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0010620,cyproheptadine,FDA,en,0
,Periactin,0,SIMPLE_CHEMICAL,bionlp,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0031017,periactin,FDA,en,0
,Megestrol Acetate,0,SIMPLE_CHEMICAL,bionlp,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0065879,megestrol acetate,FDA,en,0
,Megace,0,SIMPLE_CHEMICAL,bionlp,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0700004,Megace,FDA,en,0
,Children,0,ORGANISM,bionlp,The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia,pediatric_use,NCT00066248,C0008059,Child,FDA,en,0
,ISIS,0,GGP,craft,"A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)",pediatric_use,NCT05143957,C3383522,Isis,FDA,en,0
,ISIS 702843,0,CHEMICAL,jnlpba,"A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)",pediatric_use,NCT05143957,C3383522,Isis,FDA,en,0
,Administered,0,DISEASE,jnlpba,"A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)",pediatric_use,NCT05143957,C1521801,Having administered,FDA,en,0
,Polycythemia,0,DISEASE,jnlpba,"A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)",pediatric_use,NCT05143957,C0032461,Polycythemia,FDA,en,0
,Obesity,0,DISEASE,jnlpba,"Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities:",pediatric_use,NCT06075667,C0028754,Obesity,FDA,en,0
,ISIS,0,SIMPLE_CHEMICAL,bionlp,"A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)",pediatric_use,NCT05143957,C3383522,Isis,FDA,en,0
,Patients,0,ORGANISM,bionlp,"A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)",pediatric_use,NCT05143957,C0030705,Patients,FDA,en,0
,Mutation,0,SO,craft,A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation,pediatric_use,NCT06039384,C0026882,Mutation,FDA,en,0
,INCB099280,0,DNA,jnlpba,A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation,pediatric_use,NCT06039384,,,FDA,en,0
,KRASG12C,0,CELL_LINE,jnlpba,A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation,pediatric_use,NCT06039384,C3274012,KRAS NP_004976.2:p.G12C,FDA,en,0
,Tumors,0,DISEASE,jnlpba,A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation,pediatric_use,NCT06039384,C0027651,Neoplasms,FDA,en,0
,Solid Tumors,0,CANCER,bionlp,A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation,pediatric_use,NCT06039384,C0280100,Solid Neoplasm,FDA,en,0
,KRASG12C,0,CELL,bionlp,A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation,pediatric_use,NCT06039384,C3274012,KRAS NP_004976.2:p.G12C,FDA,en,0
,Antihistamine Medications,0,CHEBI,craft,Do Common Over-the-counter Antihistamine Medications Modify Thermoregulatory Responses During Passive Heat Stress?,adverse_reactions,NCT06217367,C0019590,Histamine Antagonists,FDA,en,0
,Antihistamine,0,CHEMICAL,jnlpba,Do Common Over-the-counter Antihistamine Medications Modify Thermoregulatory Responses During Passive Heat Stress?,adverse_reactions,NCT06217367,C0019590,Histamine Antagonists,FDA,en,0
,Antihistamine,0,SIMPLE_CHEMICAL,bionlp,Do Common Over-the-counter Antihistamine Medications Modify Thermoregulatory Responses During Passive Heat Stress?,adverse_reactions,NCT06217367,C0019590,Histamine Antagonists,FDA,en,0
,Food,0,CHEBI,craft,"The Effect of a Breakfast Meal Containing Oat β-glucan on Food Intake at a Subsequent Meal in Normal-weight and Overweight Subjects: A Randomized, Placebo-controlled Cross-over Study",warnings,NCT03490851,C0016452,Food,FDA,en,0
,Overweight,0,DISEASE,jnlpba,"The Effect of a Breakfast Meal Containing Oat β-glucan on Food Intake at a Subsequent Meal in Normal-weight and Overweight Subjects: A Randomized, Placebo-controlled Cross-over Study",warnings,NCT03490851,C0497406,Overweight,FDA,en,0
,Meal,0,GENE_OR_GENE_PRODUCT,bionlp,"The Effect of a Breakfast Meal Containing Oat β-glucan on Food Intake at a Subsequent Meal in Normal-weight and Overweight Subjects: A Randomized, Placebo-controlled Cross-over Study",warnings,NCT03490851,C1998602,Meal (occasion for eating),FDA,en,0
,DePuy P.F.C.® SigmaTM,0,PROTEIN,jnlpba,An Investigation of Computer-Assisted Total Knee Replacement Kinematics on Patient Performance: An Examination of the DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee and the DePuy P.F.C.® Sigma RP Rotating Platform Knee Systems,warnings,NCT00375856,,,FDA,en,0
,Patient,0,ORGANISM,bionlp,An Investigation of Computer-Assisted Total Knee Replacement Kinematics on Patient Performance: An Examination of the DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee and the DePuy P.F.C.® Sigma RP Rotating Platform Knee Systems,warnings,NCT00375856,C0030705,Patients,FDA,en,0
,Knee,0,CELL,bionlp,An Investigation of Computer-Assisted Total Knee Replacement Kinematics on Patient Performance: An Examination of the DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee and the DePuy P.F.C.® Sigma RP Rotating Platform Knee Systems,warnings,NCT00375856,C0022742,Knee,FDA,en,0
,Knee Systems,0,CANCER,bionlp,An Investigation of Computer-Assisted Total Knee Replacement Kinematics on Patient Performance: An Examination of the DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee and the DePuy P.F.C.® Sigma RP Rotating Platform Knee Systems,warnings,NCT00375856,,,FDA,en,0
,HF-SRT,0,CELL_LINE,jnlpba,Hypofractionated Stereotactic Radiotherapy (HF-SRT) for Large-Volume Brain Metastases,warnings,NCT00805103,,,FDA,en,0
,Brain Metastases,0,CANCER,bionlp,Hypofractionated Stereotactic Radiotherapy (HF-SRT) for Large-Volume Brain Metastases,warnings,NCT00805103,C0220650,Metastatic malignant neoplasm to brain,FDA,en,0
,Reslizumab,0,SIMPLE_CHEMICAL,bionlp,An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation,pediatric_use,NCT00587288,C1869620,reslizumab,FDA,en,0
,Airway,0,MULTI_TISSUE_STRUCTURE,bionlp,An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation,pediatric_use,NCT00587288,C0178987,Artificial Airways,FDA,en,0
,Obesity,0,DISEASE,jnlpba,Working With Parents to Prevent Childhood Obesity: A Primary Care-based Study,indications,NCT02330588,C0028754,Obesity,FDA,en,0
,Autism Spectrum Disorder,0,DISEASE,jnlpba,Deep Brain Stimulation for the Treatment of Refractory Repetitive Self-Injurious Behaviour in Children With Autism Spectrum Disorder: A Pilot Project,pregnancy,NCT03982888,C1510586,Autism Spectrum Disorders,FDA,en,0
,Brain,0,ORGAN,bionlp,Deep Brain Stimulation for the Treatment of Refractory Repetitive Self-Injurious Behaviour in Children With Autism Spectrum Disorder: A Pilot Project,pregnancy,NCT03982888,C0006104,Brain,FDA,en,0
,Children,0,ORGANISM,bionlp,Deep Brain Stimulation for the Treatment of Refractory Repetitive Self-Injurious Behaviour in Children With Autism Spectrum Disorder: A Pilot Project,pregnancy,NCT03982888,C0008059,Child,FDA,en,0
,Squamous Cell,0,CL,craft,"A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",indications,NCT03358472,C0221910,Squamous Epithelial Cells,FDA,en,0
,Head and Neck Squamous Cell Carcinoma,0,DISEASE,jnlpba,"A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",indications,NCT03358472,C1168401,Squamous cell carcinoma of the head and neck,FDA,en,0
,KEYNOTE-669/ECHO-304,0,CHEMICAL,jnlpba,"A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",indications,NCT03358472,,,FDA,en,0
,Line,0,CELL,bionlp,"A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",indications,NCT03358472,,,FDA,en,0
,Metastatic Head and Neck Squamous Cell Carcinoma,0,CANCER,bionlp,"A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",indications,NCT03358472,C0744620,Metastatic Head and Neck Squamous Cell Carcinoma,FDA,en,0
,≥,0,GGP,craft,VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study,warnings,NCT01543672,,,FDA,en,0
,Tumor,0,DISEASE,jnlpba,VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study,warnings,NCT01543672,C0027651,Neoplasms,FDA,en,0
,Tumors,0,DISEASE,jnlpba,VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study,warnings,NCT01543672,C0027651,Neoplasms,FDA,en,0
,Lung Cancer,0,DISEASE,jnlpba,VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study,warnings,NCT01543672,C0242379,Malignant neoplasm of lung,FDA,en,0
,Tumor,0,CANCER,bionlp,VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study,warnings,NCT01543672,C0027651,Neoplasms,FDA,en,0
,Lung Tumors,0,CANCER,bionlp,VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study,warnings,NCT01543672,C0024121,Lung Neoplasms,FDA,en,0
,Lung Cancer Patients,0,CANCER,bionlp,VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study,warnings,NCT01543672,C0242379,Malignant neoplasm of lung,FDA,en,0
,SBRT,0,CANCER,bionlp,VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study,warnings,NCT01543672,C3896609,Stereotactic Body Radiation Therapy,FDA,en,0
,Oxygen,0,CHEBI,craft,"FreeDom : Innovative Strategy for the Management of COPD Exacerbations Combining Early Hospitalisation Discharge, Automated Oxygen Weaning at Home, Telemedicine and Tele-rehabilitation",adverse_reactions,NCT03396172,C0030054,oxygen,FDA,en,0
,COPD Exacerbations,0,DISEASE,jnlpba,"FreeDom : Innovative Strategy for the Management of COPD Exacerbations Combining Early Hospitalisation Discharge, Automated Oxygen Weaning at Home, Telemedicine and Tele-rehabilitation",adverse_reactions,NCT03396172,C0024117,Chronic Obstructive Airway Disease,FDA,en,0
,Oxygen,0,CHEMICAL,jnlpba,"FreeDom : Innovative Strategy for the Management of COPD Exacerbations Combining Early Hospitalisation Discharge, Automated Oxygen Weaning at Home, Telemedicine and Tele-rehabilitation",adverse_reactions,NCT03396172,C0030054,oxygen,FDA,en,0
,COPD,0,PATHOLOGICAL_FORMATION,bionlp,"FreeDom : Innovative Strategy for the Management of COPD Exacerbations Combining Early Hospitalisation Discharge, Automated Oxygen Weaning at Home, Telemedicine and Tele-rehabilitation",adverse_reactions,NCT03396172,C0024117,Chronic Obstructive Airway Disease,FDA,en,0
,Oxygen,0,SIMPLE_CHEMICAL,bionlp,"FreeDom : Innovative Strategy for the Management of COPD Exacerbations Combining Early Hospitalisation Discharge, Automated Oxygen Weaning at Home, Telemedicine and Tele-rehabilitation",adverse_reactions,NCT03396172,C0030054,oxygen,FDA,en,0
,Propofol,0,GGP,craft,Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients,geriatric_use,NCT01151254,C0033487,propofol,FDA,en,0
,Anesthetics,0,CHEBI,craft,Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients,geriatric_use,NCT01151254,C0002930,Anesthesiology,FDA,en,0
,Propofol,0,CHEMICAL,jnlpba,Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients,geriatric_use,NCT01151254,C0033487,propofol,FDA,en,0
,Propofol,0,SIMPLE_CHEMICAL,bionlp,Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients,geriatric_use,NCT01151254,C0033487,propofol,FDA,en,0
,PA,0,GENE_OR_GENE_PRODUCT,bionlp,Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients,geriatric_use,NCT01151254,C0030853,Pennsylvania,FDA,en,0
,Cardiac,0,ORGAN,bionlp,Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients,geriatric_use,NCT01151254,C0018787,Heart,FDA,en,0
,Patients,0,ORGANISM,bionlp,Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients,geriatric_use,NCT01151254,C0030705,Patients,FDA,en,0
,Overweight,0,DISEASE,jnlpba,"Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities:",pediatric_use,NCT06075667,C0497406,Overweight,FDA,en,0
,Heart Defects,0,DISEASE,jnlpba,Optimizing Health Among Children With Congenital Heart Defects Through Rehabilitation Focused on Physical Activity Determinants,mechanism_of_action,NCT00974688,C0018798,Congenital Heart Defects,FDA,en,0
,Children,0,ORGANISM,bionlp,Optimizing Health Among Children With Congenital Heart Defects Through Rehabilitation Focused on Physical Activity Determinants,mechanism_of_action,NCT00974688,C0008059,Child,FDA,en,0
,Heart,0,ORGAN,bionlp,Optimizing Health Among Children With Congenital Heart Defects Through Rehabilitation Focused on Physical Activity Determinants,mechanism_of_action,NCT00974688,,,FDA,en,0
,AML,0,GGP,craft,Detection of Minimal Residual Disease in Children Receiving Therapy for AML or MDS,indications,NCT00003790,C0023467,"Leukemia, Myelocytic, Acute",FDA,en,0
,AML,0,DISEASE,jnlpba,Detection of Minimal Residual Disease in Children Receiving Therapy for AML or MDS,indications,NCT00003790,C0023467,"Leukemia, Myelocytic, Acute",FDA,en,0
,Children,0,ORGANISM,bionlp,Detection of Minimal Residual Disease in Children Receiving Therapy for AML or MDS,indications,NCT00003790,C0008059,Child,FDA,en,0
,AML,0,CANCER,bionlp,Detection of Minimal Residual Disease in Children Receiving Therapy for AML or MDS,indications,NCT00003790,C0023467,"Leukemia, Myelocytic, Acute",FDA,en,0
,Hodgkin Lymphoma,0,DISEASE,jnlpba,A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma,indications,NCT05675410,C0019829,Hodgkin Disease,FDA,en,0
,Children,0,CANCER,bionlp,A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma,indications,NCT05675410,C0008059,Child,FDA,en,0
,Diabetes,0,DISEASE,jnlpba,Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease,indications,NCT06217302,C0011847,Diabetes,FDA,en,0
,Diabetic Kidney Disease,0,DISEASE,jnlpba,Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease,indications,NCT06217302,C0011881,Diabetic Nephropathy,FDA,en,0
,Kidney,0,ORGAN,bionlp,Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease,indications,NCT06217302,C0022646,Kidney,FDA,en,0
,Type 1,0,GENE_OR_GENE_PRODUCT,bionlp,Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease,indications,NCT06217302,C0441729,Type 1,FDA,en,0
,Kidney Disease,0,CANCER,bionlp,Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease,indications,NCT06217302,C0022658,Kidney Diseases,FDA,en,0
,Autism Spectrum Disorders,0,DISEASE,jnlpba,Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders,indications,NCT02153203,C1510586,Autism Spectrum Disorders,FDA,en,0
,Children,0,ORGANISM,bionlp,Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders,indications,NCT02153203,C0008059,Child,FDA,en,0
,Migraine,0,DISEASE,jnlpba,"A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.",pediatric_use,NCT05711394,C0149931,Migraine Disorders,FDA,en,0
,Sorafenib,0,GGP,craft,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C1516119,sorafenib,FDA,en,0
,Refractory,0,TAXON,craft,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C0205269,Unresponsive to Treatment,FDA,en,0
,NANT,0,CHEMICAL,jnlpba,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,,,FDA,en,0
,Sorafenib,0,CHEMICAL,jnlpba,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C1516119,sorafenib,FDA,en,0
,Relapsed,0,DISEASE,jnlpba,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C0205336,Relapsing course,FDA,en,0
,Neuroblastoma,0,DISEASE,jnlpba,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C0027819,Neuroblastoma,FDA,en,0
,NANT N2013-02 A Phase I,0,GENE_OR_GENE_PRODUCT,bionlp,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,,,FDA,en,0
,Sorafenib,0,SIMPLE_CHEMICAL,bionlp,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C1516119,sorafenib,FDA,en,0
,Patients,0,ORGANISM,bionlp,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C0030705,Patients,FDA,en,0
,Relapsed,0,CANCER,bionlp,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C0205336,Relapsing course,FDA,en,0
,Neuroblastoma,0,CANCER,bionlp,NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,pediatric_use,NCT02298348,C0027819,Neuroblastoma,FDA,en,0
,Vaccine,0,TAXON,craft,"A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85",pediatric_use,NCT04473690,C0042210,Vaccines,FDA,en,0
,TAP-COVID-19 SARS-CoV-2 Vaccine,0,DISEASE,jnlpba,"A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85",pediatric_use,NCT04473690,C5387588,COVID-19 Vaccines,FDA,en,0
,First-in-human,0,SIMPLE_CHEMICAL,bionlp,"A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85",pediatric_use,NCT04473690,C4684677,First-in-Human Study,FDA,en,0
,Hearts,0,ORGANISM,bionlp,Healing Hearts Together: Evaluating a Couples-based Intervention to Improve Health Outcomes,indications,NCT03938116,C0018787,Heart,FDA,en,0
,Germ Cell,0,CL,craft,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0017471,Germ Cells,FDA,en,0
,Ifosfamide,0,CHEBI,craft,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0020823,ifosfamide,FDA,en,0
,Carboplatin,0,GGP,craft,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0079083,carboplatin,FDA,en,0
,Tumors,0,DISEASE,jnlpba,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0027651,Neoplasms,FDA,en,0
,Paclitaxel,0,CHEMICAL,jnlpba,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0144576,paclitaxel,FDA,en,0
,Ifosfamide,0,CHEMICAL,jnlpba,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0020823,ifosfamide,FDA,en,0
,Carboplatin,0,CHEMICAL,jnlpba,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0079083,carboplatin,FDA,en,0
,Malignant Germ Cell Tumors,0,CANCER,bionlp,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C4048549,Malignant germ cell neoplasm,FDA,en,0
,Paclitaxel,0,SIMPLE_CHEMICAL,bionlp,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0144576,paclitaxel,FDA,en,0
,Ifosfamide,0,SIMPLE_CHEMICAL,bionlp,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0020823,ifosfamide,FDA,en,0
,Carboplatin,0,SIMPLE_CHEMICAL,bionlp,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",pediatric_use,NCT00467051,C0079083,carboplatin,FDA,en,0
,Epcoritamab,0,CHEMICAL,jnlpba,"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",pediatric_use,NCT05578976,C5418281,Epcoritamab,FDA,en,0
,R-CHOP,0,CHEMICAL,jnlpba,"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",pediatric_use,NCT05578976,C0393023,R-CHOP Regimen,FDA,en,0
,B-Cell Lymphoma,0,DISEASE,jnlpba,"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",pediatric_use,NCT05578976,C0079731,B-Cell Lymphomas,FDA,en,0
,DLBCL,0,DISEASE,jnlpba,"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",pediatric_use,NCT05578976,C0079744,Diffuse Large B-Cell Lymphoma,FDA,en,0
,Epcoritamab,0,ORGANISM_SUBSTANCE,bionlp,"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",pediatric_use,NCT05578976,C5418281,Epcoritamab,FDA,en,0
,R-CHOP,0,SIMPLE_CHEMICAL,bionlp,"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",pediatric_use,NCT05578976,C0393023,R-CHOP Regimen,FDA,en,0
,Diffuse Large B-Cell Lymphoma,0,CANCER,bionlp,"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",pediatric_use,NCT05578976,C0079744,Diffuse Large B-Cell Lymphoma,FDA,en,0
,DLBCL,0,CANCER,bionlp,"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",pediatric_use,NCT05578976,C0079744,Diffuse Large B-Cell Lymphoma,FDA,en,0
,Pulmonary Arterial Hypertension,0,DISEASE,jnlpba,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients",warnings,NCT04811092,C2973725,Pulmonary arterial hypertension,FDA,en,0
,PAH,0,CHEMICAL,jnlpba,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients",warnings,NCT04811092,C0030123,4-aminohippuric acid,FDA,en,0
,Relapsed,0,CANCER,bionlp,"A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms",pediatric_use,NCT03493451,C0205336,Relapsing course,FDA,en,0
,Sotatercept,0,GENE_OR_GENE_PRODUCT,bionlp,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients",warnings,NCT04811092,C2699571,Sotatercept,FDA,en,0
,Pulmonary Arterial,0,MULTI_TISSUE_STRUCTURE,bionlp,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients",warnings,NCT04811092,C0034052,Pulmonary artery structure,FDA,en,0
,Patients,0,ORGANISM,bionlp,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients",warnings,NCT04811092,C0030705,Patients,FDA,en,0
,Glycemic,0,CHEBI,craft,Determination of the Postprandial Glycemic Response and Glycemic Index of Nutritional Products: A Randomized Controlled Clinical Trial in Healthy Individuals,warnings,NCT06215534,C1136206,Glycemic Index,FDA,en,0
,Individuals,0,TAXON,craft,Determination of the Postprandial Glycemic Response and Glycemic Index of Nutritional Products: A Randomized Controlled Clinical Trial in Healthy Individuals,warnings,NCT06215534,C0027361,Persons,FDA,en,0
,Nutritional Products: A,0,PROTEIN,jnlpba,Determination of the Postprandial Glycemic Response and Glycemic Index of Nutritional Products: A Randomized Controlled Clinical Trial in Healthy Individuals,warnings,NCT06215534,C4036031,Nutritional products,FDA,en,0
,Postprandial,0,IMMATERIAL_ANATOMICAL_ENTITY,bionlp,Determination of the Postprandial Glycemic Response and Glycemic Index of Nutritional Products: A Randomized Controlled Clinical Trial in Healthy Individuals,warnings,NCT06215534,C0376674,Postprandial Period,FDA,en,0
,Emission Tomography,0,DNA,jnlpba,"The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial",warnings,NCT00265356,C0032743,Positron-Emission Tomography,FDA,en,0
,Positron,0,CHEMICAL,jnlpba,"The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial",warnings,NCT00265356,C0032744,Positrons,FDA,en,0
,Colorectal Adenocarcinoma,0,DISEASE,jnlpba,"The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial",warnings,NCT00265356,C1319315,Adenocarcinoma of large intestine,FDA,en,0
,Liver,0,ORGAN,bionlp,"The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial",warnings,NCT00265356,C0023884,Liver,FDA,en,0
,Colorectal Adenocarcinoma,0,CANCER,bionlp,"The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial",warnings,NCT00265356,C1319315,Adenocarcinoma of large intestine,FDA,en,0
,CD34+,0,GGP,craft,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,,,FDA,en,0
,G-CSF,0,PROTEIN,jnlpba,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,C0079459,Granulocyte Colony-Stimulating Factor,FDA,en,0
,≥ 6*10^6,0,PROTEIN,jnlpba,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,,,FDA,en,0
,Cells/kg,0,DNA,jnlpba,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,C3899697,Cells per Kilogram,FDA,en,0
,AMD3100,0,CHEMICAL,jnlpba,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,C0662900,AMD 3100,FDA,en,0
,G-CSF,0,CHEMICAL,jnlpba,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,C0079459,Granulocyte Colony-Stimulating Factor,FDA,en,0
,AMD3100,0,SIMPLE_CHEMICAL,bionlp,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,C0662900,AMD 3100,FDA,en,0
,G-CSF,0,GENE_OR_GENE_PRODUCT,bionlp,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,C0079459,Granulocyte Colony-Stimulating Factor,FDA,en,0
,CD34,0,GENE_OR_GENE_PRODUCT,bionlp,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,C0054953,CD34 Antigens,FDA,en,0
,Myeloma Patients,0,CANCER,bionlp,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation",adverse_reactions,NCT00103662,C0026764,Multiple Myeloma,FDA,en,0
,T-,0,CELL,bionlp,"A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms",pediatric_use,NCT03493451,,,FDA,en,0
,Rituximab,0,TAXON,craft,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C0393022,rituximab,FDA,en,0
,R2,0,DNA,jnlpba,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,,,FDA,en,0
,EPCORE,0,PROTEIN,jnlpba,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,,,FDA,en,0
,Epcoritamab,0,CHEMICAL,jnlpba,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C5418281,Epcoritamab,FDA,en,0
,Rituximab,0,CHEMICAL,jnlpba,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C0393022,rituximab,FDA,en,0
,Lenalidomide,0,CHEMICAL,jnlpba,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C1144149,lenalidomide,FDA,en,0
,Relapsed,0,DISEASE,jnlpba,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C0205336,Relapsing course,FDA,en,0
,Follicular Lymphoma,0,DISEASE,jnlpba,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C0024301,"Lymphoma, Follicular",FDA,en,0
,Epcoritamab,0,ORGANISM_SUBSTANCE,bionlp,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C5418281,Epcoritamab,FDA,en,0
,Rituximab,0,SIMPLE_CHEMICAL,bionlp,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C0393022,rituximab,FDA,en,0
,Lenalidomide,0,SIMPLE_CHEMICAL,bionlp,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C1144149,lenalidomide,FDA,en,0
,Relapsed,0,CANCER,bionlp,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C0205336,Relapsing course,FDA,en,0
,Follicular Lymphoma,0,CANCER,bionlp,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)",pediatric_use,NCT05409066,C0024301,"Lymphoma, Follicular",FDA,en,0
,Adjuvant,0,CHEMICAL,jnlpba,"A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)",adverse_reactions,NCT05933577,C0001551,Immunologic Adjuvants,FDA,en,0
,Pembrolizumab,0,CHEMICAL,jnlpba,"A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)",adverse_reactions,NCT05933577,C3658706,pembrolizumab,FDA,en,0
,Melanoma,0,DISEASE,jnlpba,"A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)",adverse_reactions,NCT05933577,C0025202,melanoma,FDA,en,0
,INTerpath-001,0,DISEASE,jnlpba,"A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)",adverse_reactions,NCT05933577,,,FDA,en,0
,Stage II-IV Melanoma,0,CANCER,bionlp,"A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)",adverse_reactions,NCT05933577,,,FDA,en,0
,Non-small Cell,0,CL,craft,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0445128,Non-small cell,FDA,en,0
,ALK-positive Non-small Cell Lung Cancer,0,DISEASE,jnlpba,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0007131,Non-Small Cell Lung Carcinoma,FDA,en,0
,NSCLC,0,DISEASE,jnlpba,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0007131,Non-Small Cell Lung Carcinoma,FDA,en,0
,NK-cell Neoplasms,0,CANCER,bionlp,"A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms",pediatric_use,NCT03493451,C1334640,Mature T-Cell and NK-Cell Neoplasm,FDA,en,0
,Leptomeninges,0,DISEASE,jnlpba,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0228126,Leptomeninges,FDA,en,0
,Five-arm,0,SIMPLE_CHEMICAL,bionlp,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,,,FDA,en,0
,Oral,0,ORGAN,bionlp,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0226896,Oral cavity,FDA,en,0
,Patients,0,ORGANISM,bionlp,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0030705,Patients,FDA,en,0
,ALK-positive Non-small Cell Lung Cancer,0,CANCER,bionlp,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0007131,Non-Small Cell Lung Carcinoma,FDA,en,0
,NSCLC,0,CANCER,bionlp,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0007131,Non-Small Cell Lung Carcinoma,FDA,en,0
,Brain,0,ORGAN,bionlp,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",pediatric_use,NCT02336451,C0006104,Brain,FDA,en,0
,Stannous Fluoride,0,CHEBI,craft,A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices,warnings,NCT03160703,C0038143,stannous fluoride,FDA,en,0
,Stannous Fluoride Dentifrices,0,DNA,jnlpba,A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices,warnings,NCT03160703,C0038143,stannous fluoride,FDA,en,0
,Stannous Fluoride,0,CHEMICAL,jnlpba,A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices,warnings,NCT03160703,C0038143,stannous fluoride,FDA,en,0
,Stannous Fluoride,0,SIMPLE_CHEMICAL,bionlp,A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices,warnings,NCT03160703,C0038143,stannous fluoride,FDA,en,0
,Oxaliplatin,0,CHEBI,craft,A Phase II Study of Oxaliplatin in Urothelial Cancer,pediatric_use,NCT00004203,C0069717,oxaliplatin,FDA,en,0
,Oxaliplatin,0,PROTEIN,jnlpba,A Phase II Study of Oxaliplatin in Urothelial Cancer,pediatric_use,NCT00004203,C0069717,oxaliplatin,FDA,en,0
,Oxaliplatin,0,CHEMICAL,jnlpba,A Phase II Study of Oxaliplatin in Urothelial Cancer,pediatric_use,NCT00004203,C0069717,oxaliplatin,FDA,en,0
,Urothelial Cancer,0,DISEASE,jnlpba,A Phase II Study of Oxaliplatin in Urothelial Cancer,pediatric_use,NCT00004203,C4049507,Recurrent Urothelial Carcinoma,FDA,en,0
,Oxaliplatin,0,SIMPLE_CHEMICAL,bionlp,A Phase II Study of Oxaliplatin in Urothelial Cancer,pediatric_use,NCT00004203,C0069717,oxaliplatin,FDA,en,0
,Urothelial Cancer,0,CANCER,bionlp,A Phase II Study of Oxaliplatin in Urothelial Cancer,pediatric_use,NCT00004203,C4049507,Recurrent Urothelial Carcinoma,FDA,en,0
,Skin,0,ORGAN,bionlp,CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee - A Vanguard Randomized Controlled Registry Trial (CLEAN Joint Trial),adverse_reactions,NCT05828810,C0444099,Skin Specimen,FDA,en,0
,Joint,0,MULTI_TISSUE_STRUCTURE,bionlp,CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee - A Vanguard Randomized Controlled Registry Trial (CLEAN Joint Trial),adverse_reactions,NCT05828810,,,FDA,en,0
,Knee - A,0,CANCER,bionlp,CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee - A Vanguard Randomized Controlled Registry Trial (CLEAN Joint Trial),adverse_reactions,NCT05828810,C0022742,Knee,FDA,en,0
,Serotonin,0,CHEMICAL,jnlpba,Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression,warnings,NCT00056472,C0036751,serotonin,FDA,en,0
,Psychotic Depression,0,DISEASE,jnlpba,Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression,warnings,NCT00056472,C0743072,"Depression, psychotic",FDA,en,0
,Serotonin Reuptake,0,GENE_OR_GENE_PRODUCT,bionlp,Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression,warnings,NCT00056472,C1621749,5-hydroxytryptamine uptake,FDA,en,0
,R-CHOP-like,0,GGP,craft,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,,,FDA,en,0
,B-cell Lymphoma,0,DISEASE,jnlpba,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,C0079731,B-Cell Lymphomas,FDA,en,0
,R-CHOP,0,CHEMICAL,jnlpba,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,C0393023,R-CHOP Regimen,FDA,en,0
,Blood Cells,0,CELL,bionlp,Age of Red Blood Cells in Premature Infants Study (ARIPI),pediatric_use,NCT00326924,C0005773,Blood Cells,FDA,en,0
,R-CHOP-like,0,CHEMICAL,jnlpba,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,,,FDA,en,0
,Zevalin,0,SIMPLE_CHEMICAL,bionlp,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,C0919274,Zevalin,FDA,en,0
,Patients,0,ORGANISM,bionlp,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,C0030705,Patients,FDA,en,0
,Diffuse Large B-cell Lymphoma,0,CANCER,bionlp,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,C0079744,Diffuse Large B-Cell Lymphoma,FDA,en,0
,R-CHOP,0,SIMPLE_CHEMICAL,bionlp,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,C0393023,R-CHOP Regimen,FDA,en,0
,R-CHOP-like,0,SIMPLE_CHEMICAL,bionlp,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",geriatric_use,NCT01510184,,,FDA,en,0
,Polymorphism,0,SO,craft,Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis,indications,NCT01935102,C0032529,Genetic Polymorphism,FDA,en,0
,Bevacizumab,0,CHEMICAL,jnlpba,Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis,indications,NCT01935102,C0796392,bevacizumab,FDA,en,0
,Breast Cancer,0,DISEASE,jnlpba,Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis,indications,NCT01935102,C0006142,Malignant neoplasm of breast,FDA,en,0
,Bevacizumab,0,SIMPLE_CHEMICAL,bionlp,Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis,indications,NCT01935102,C0796392,bevacizumab,FDA,en,0
,Breast Cancer Patients,0,CANCER,bionlp,Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis,indications,NCT01935102,C0006142,Malignant neoplasm of breast,FDA,en,0
,O2,0,CHEBI,craft,Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study,adverse_reactions,NCT02144090,C0030054,oxygen,FDA,en,0
,O2 Pilot,0,CHEMICAL,jnlpba,Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study,adverse_reactions,NCT02144090,C0030054,oxygen,FDA,en,0
,O2,0,SIMPLE_CHEMICAL,bionlp,Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study,adverse_reactions,NCT02144090,C0030054,oxygen,FDA,en,0
,Children,0,ORGANISM,bionlp,Non-invasive Ventilation Generated by External Chest Pressure in Children,warnings,NCT01394172,C0008059,Child,FDA,en,0
,IMGN853,0,DNA,jnlpba,"A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",pediatric_use,NCT01609556,C3640818,IMGN853,FDA,en,0
,Ovarian Cancer,0,DISEASE,jnlpba,"A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",pediatric_use,NCT01609556,C0919267,ovarian neoplasm,FDA,en,0
,Tumors,0,DISEASE,jnlpba,"A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",pediatric_use,NCT01609556,C0027651,Neoplasms,FDA,en,0
,First-in-Human,0,ORGANISM,bionlp,"A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",pediatric_use,NCT01609556,C4684677,First-in-Human Study,FDA,en,0
,Ovarian Cancer,0,CANCER,bionlp,"A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",pediatric_use,NCT01609556,C0919267,ovarian neoplasm,FDA,en,0
,Solid Tumors,0,CANCER,bionlp,"A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",pediatric_use,NCT01609556,C0280100,Solid Neoplasm,FDA,en,0
,Cardiac,0,ORGAN,bionlp,Design and Evaluation of a Brief Motivational Intervention to Promote Enrolment in Outpatient Cardiac Rehabilitation,adverse_reactions,NCT02721758,C0018787,Heart,FDA,en,0
,Intravenous,0,CHEBI,craft,A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage,warnings,NCT00257803,C0348016,Intravenous,FDA,en,0
,5 Unit,0,DNA,jnlpba,A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage,warnings,NCT00257803,,,FDA,en,0
,Oxytocin,0,CHEMICAL,jnlpba,A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage,warnings,NCT00257803,C0030095,oxytocin,FDA,en,0
,Intravenous Oxytocin Bolus Versus,0,IMMATERIAL_ANATOMICAL_ENTITY,bionlp,A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage,warnings,NCT00257803,C0348016,Intravenous,FDA,en,0
,Uterine,0,ORGAN,bionlp,A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage,warnings,NCT00257803,C0042149,Uterus,FDA,en,0
,Cesarean,0,ANATOMICAL_SYSTEM,bionlp,A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage,warnings,NCT00257803,C3841297,Cesarean,FDA,en,0
,Women,0,ORGANISM,bionlp,A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage,warnings,NCT00257803,C0043210,Woman,FDA,en,0
,Vitamin B12,0,CHEBI,craft,"Efficacy of The Daily Consumption of Vitamin B12 Fortified Yoghurt on Vitamin B12 Status of Healthy Older Adults - A Double-blind, Randomized Controlled Trial",warnings,NCT05993962,C0042845,vitamin B12,FDA,en,0
,B12,0,PROTEIN,jnlpba,"Efficacy of The Daily Consumption of Vitamin B12 Fortified Yoghurt on Vitamin B12 Status of Healthy Older Adults - A Double-blind, Randomized Controlled Trial",warnings,NCT05993962,,,FDA,en,0
,Vitamin B12,0,CHEMICAL,jnlpba,"Efficacy of The Daily Consumption of Vitamin B12 Fortified Yoghurt on Vitamin B12 Status of Healthy Older Adults - A Double-blind, Randomized Controlled Trial",warnings,NCT05993962,C0042845,vitamin B12,FDA,en,0
,Vitamin B12,0,SIMPLE_CHEMICAL,bionlp,"Efficacy of The Daily Consumption of Vitamin B12 Fortified Yoghurt on Vitamin B12 Status of Healthy Older Adults - A Double-blind, Randomized Controlled Trial",warnings,NCT05993962,C0042845,vitamin B12,FDA,en,0
,Adults - A,0,CANCER,bionlp,"Efficacy of The Daily Consumption of Vitamin B12 Fortified Yoghurt on Vitamin B12 Status of Healthy Older Adults - A Double-blind, Randomized Controlled Trial",warnings,NCT05993962,C0001675,Adult,FDA,en,0
,Insulin,0,GGP,craft,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0021641,Insulin,FDA,en,0
,Fatty Acids,0,CHEBI,craft,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0015684,Fatty Acids,FDA,en,0
,Inositols,0,CHEBI,craft,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0021547,inositol,FDA,en,0
,Insulin,0,PROTEIN,jnlpba,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0021641,Insulin,FDA,en,0
,Hyperandrogenism,0,DISEASE,jnlpba,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0206081,Hyperandrogenism,FDA,en,0
,Inositols,0,CHEMICAL,jnlpba,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0021547,inositol,FDA,en,0
,Polycystic Ovary Syndrome,0,DISEASE,jnlpba,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0032460,Polycystic Ovary Syndrome,FDA,en,0
,Insulin,0,GENE_OR_GENE_PRODUCT,bionlp,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0021641,Insulin,FDA,en,0
,Free Fatty Acids,0,SIMPLE_CHEMICAL,bionlp,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0015688,Nonesterified Fatty Acids,FDA,en,0
,Inositols,0,SIMPLE_CHEMICAL,bionlp,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0021547,inositol,FDA,en,0
,Women,0,ORGANISM,bionlp,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0043210,Woman,FDA,en,0
,Polycystic Ovary,0,CANCER,bionlp,Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome,mechanism_of_action,NCT01019356,C0032460,Polycystic Ovary Syndrome,FDA,en,0
,ABBV-8E12,0,CHEMICAL,jnlpba,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease",pediatric_use,NCT02880956,C4742538,ABBV-8E12,FDA,en,0
,Alzheimer's Disease,0,DISEASE,jnlpba,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease",pediatric_use,NCT02880956,C0002395,Alzheimer's Disease,FDA,en,0
,Environmental Factors,0,PROTEIN,jnlpba,"A Pan-Canadian, Multi-ethnic Cohort Study in Healthy Participants Aimed to Better Understand the Impact of Individual, Socioeconomic and Other Environmental Factors Leading to Cardiac and Vascular Disease",indications,NCT02220582,C1516998,Exogenous Factors,FDA,en,0
,Cardiac,0,CELL,bionlp,"A Pan-Canadian, Multi-ethnic Cohort Study in Healthy Participants Aimed to Better Understand the Impact of Individual, Socioeconomic and Other Environmental Factors Leading to Cardiac and Vascular Disease",indications,NCT02220582,C0018787,Heart,FDA,en,0
